Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 5136-5146
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5136
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5136
Table 2 Immunohistochemical findings in patients with fibroblastic rheumatism with available data
| Immunohistochemical markers | Reactivity | Number of patients with available data (n/N, %) |
| CD34 | + | 5/20 (62.5) |
| - | 15/20 (62.5) | |
| S100 | + | 4/23 (71.88) |
| - | 19/23 (71.88) | |
| EMA | + | 1/10 (31.25) |
| - | 9/10 (31.25) | |
| α-SMA | + | 25/28 (87.5) |
| - | 3/28 (87.5) | |
| Vimentin | + | 18/18 (56.25) |
| - | 0/18 (56.25) | |
| CD68 | + | 2/12 (37.5) |
| - | 10/12 (37.5) |
- Citation: Guo H, Liang Q, Dong C, Zhang Q, Gu ZF. Systematic review of fibroblastic rheumatism: A case report. World J Clin Cases 2023; 11(21): 5136-5146
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5136.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5136